Physician profile
Rachel E Starr
NPI 1003202037
$2,089.67
in general payments reported to CMS, 2019-2025
22 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $66.54 · 2022: $63.65 · 2023: $606 · 2024: $293 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,370 · Travel and Lodging: $370 · Long Term Medical Supply Or Device Loan: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,369.87 |
| Travel and Lodging | $369.65 |
| Long Term Medical Supply Or Device Loan | $219.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $571.73 | 2023-2025 | Minimed 780g |
| Abbott Laboratories | $313.82 | 2023-2025 | Freestyle Copilot, Freestyle Libre 3 |
| Novo Nordisk INC | $298.26 | 2022-2025 | Ozempic, Rybelsus |
| Beta Bionics, INC. | $164.92 | 2023-2024 | Ilet Bionic Pancreas |
| Corcept Therapeutics | $153.09 | 2024-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $133.61 | 2024 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $87.41 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $41.76 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.04 | 2023 | Jardiance |
| Dexcom, INC. | $32.57 | 2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $30.64 | 2023-2024 | Mounjaro |
| Pfizer INC. | $30.11 | 2021-2022 | |
| Radius Health, INC. | $28.93 | 2025 | Tymlos |
| Sequel Med Tech, LLC | $28.06 | 2025 | Twiist |
| Amryt Pharma Holdings LTD | $24.60 | 2023 | Mycapssa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $22.44 | 2025 | Isturisa |
| Bayer Healthcare Pharmaceuticals INC. | $21.59 | 2022 | |
| Ascensia Diabetes Care US INC. | $18.11 | 2024 | |
| Cequr Corporation | $15.31 | 2024 | Cequr Simplicity |
| Viiv Healthcare Company | $14.16 | 2023 | Apretude |
| Insulet Corporation | $13.52 | 2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Starr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.